Join
Live feed
·
PRReleasevia Quantisnow
Radiopharm Theranostics Limited logo

Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
RADX· Radiopharm Theranostics Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RADX (Radiopharm Theranostics Limited) and more on Quantisnow.